Company intelligence / Profile preview

Diatide

Londonderry, New Hampshire, USA

Ownership: Private
Development stage: Other

Overview

Diatide was a biotechnology company focused on the development of peptide-based radiopharmaceuticals for diagnostic imaging and therapeutic applications. The company's core technology involved synthetic peptides designed to bind specifically to receptors on diseased cells, which were then labeled with technetium-99m for imaging. Diatide successfully brought two products to market: NeoTect, used for evaluating solitary pulmonary nodules, and AcuTect, used for detecting acute venous thrombosis. The company was acquired by Schering AG in 1999 to bolster its diagnostic imaging portfolio.

Therapeutic areas: OncologyCardiovascularPulmonology
Modalities: RadiopharmaceuticalPeptides
Industry: Biotech

Partnerships

Nycomed AmershamBerlex Laboratories

Beyond the preview

Go deeper on Diatide.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diatide.

Explore the full profile